Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIR645 in mild allergic asthma
NCT00941577Phase 2Completed
- Sponsor
- Altair Therapeutics, Inc.
- Start
- Oct 2009
- Primary completion
- May 2010
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma comparing AIR645 with Placebo (2 arms). Primary endpoint: Area under the curve of the percentage decrease in forced expiratory volume in one second from baseline at 36 days. Started Oct 2009; status: completed.
02
Drugs
AIR645
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00941577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941577.